AlloVir, Inc. ALVR
Set alert
At close · Mar 18
52-week range unavailable
- Open
- 9.55
- Prev close
- 9.81
- Mkt cap
- 54.80M
- Vol
- 9.40K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.55
- High
- 10.32
- Forward P/E
- -1.48
- Beta
- 0.74
- Short ratio
- 20.03
- Inst. own
- 41.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.65036
- 200-d avg
- 0.736615
- 1y target
- 1.50
Key statistics
- Market cap
- 54.80M
- Enterprise value
- -58.81M
- Trailing P/E
- 0.00
- Forward P/E
- -1.48
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.36
- EPS (TTM)
- -0.88
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -58.26M
- Total cash
- 129.61M
- Total debt
- 9.00M
- Return on equity
- -80.33%
- Shares outstanding
- 115.57M
- Short % of float
- 6.34%
- 50-day average
- 0.65036
- 200-day average
- 0.736615
Analyst view
Consensus: none
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.14 | -0.04 | +0.10 | +71.43% |
| Aug 9, 2024 | Jun 1, 2024 | -0.10 | -0.05 | +0.05 | +50.00% |
| May 13, 2024 | Mar 1, 2024 | -0.16 | -0.18 | -0.02 | -12.50% |
| Mar 15, 2024 | Dec 1, 2023 | -0.43 | -0.53 | -0.10 | -23.26% |
| Nov 2, 2023 | Sep 1, 2023 | -0.42 | -0.39 | +0.03 | +7.14% |
| Aug 3, 2023 | Jun 1, 2023 | -0.45 | -0.48 | -0.03 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 26, 2023 | B of A Securities | down | Buy | Underperform |
| Dec 22, 2023 | Leerink Partners | down | Outperform | Market Perform |
| Dec 22, 2023 | Piper Sandler | down | Overweight | Neutral |
| Dec 22, 2023 | JP Morgan | down | Overweight | Underweight |
| Aug 18, 2023 | B of A Securities | init | — | Buy |
| Aug 7, 2023 | Morgan Stanley | reit | Overweight | Overweight |
About AlloVir, Inc.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- allovir.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ALVR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORNSTEIN JEFFREY S | Director | Stock Award(Grant) | Jun 5, 2024 | 110,197 |
| BRAINARD DIANA | Chief Executive Officer | Sale | Nov 18, 2024 | 723,363 |
| BRENNER MALCOLM | Director | Stock Award(Grant) | Jun 5, 2024 | 263,929 |
| HAGEN BRETT R. | Officer | Sale | Nov 18, 2024 | 68,506 |
| HALLAL DAVID L | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 5, 2024 | 19,677,500 |
| JOVAN-EMBIRICOS MORANA | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 5, 2024 | 26,603,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 9.77% | 11,294,585 | 5.36M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.69% | 11,202,000 | 5.31M | Sep 29, 2024 |
| Siren, L.L.C. | 5.71% | 6,597,167 | 3.13M | Sep 29, 2024 |
| Millennium Management Llc | 2.84% | 3,284,800 | 1.56M | Sep 29, 2024 |
| Vanguard Group Inc | 2.29% | 2,647,010 | 1.26M | Sep 29, 2024 |
| Redmile Group, LLC | 1.65% | 1,907,969 | 904.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 1,771,721 | 840.15K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.74% | 858,612 | 407.15K | Sep 29, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.25% | 288,696 | 136.90K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 286,410 | 135.81K | Oct 30, 2024 |
| Variable Insurance Products Fd II-Disciplined Small Cap Portfolio | 0.16% | 179,553 | 85.14K | Sep 29, 2024 |
| Fidelity Enhanced Small Cap ETF | 0.10% | 120,724 | 57.25K | Oct 30, 2024 |